Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme
- 1 October 2004
- journal article
- clinical trial
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 60 (2) , 353-357
- https://doi.org/10.1016/j.ijrobp.2004.04.023
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Phase II Study of Temozolomide Plus Thalidomide for the Treatment of Metastatic MelanomaJournal of Clinical Oncology, 2003
- Thalidomide Metabolites and Analogues. 3. Synthesis and Antiangiogenic Activity of the Teratogenic and TNFα-Modulatory Thalidomide Analogue 2-(2,6-Dioxopiperidine-3-yl)phthalimidineJournal of Medicinal Chemistry, 2003
- Randomized Phase II Study of Temozolomide Given Every 8 Hours or Daily With Either Interferon Alfa-2b or Thalidomide in Metastatic Malignant MelanomaJournal of Clinical Oncology, 2003
- Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade GliomasJournal of Clinical Oncology, 2003
- Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trialsThe Lancet, 2002
- Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant TemozolomideJournal of Clinical Oncology, 2002
- A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseBritish Journal of Cancer, 2000
- Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascadeImmunopharmacology, 1996
- Recursive Partitioning Analysis of Prognostic Factors in Three Radiation Therapy Oncology Group Malignant Glioma TrialsJNCI Journal of the National Cancer Institute, 1993
- Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.The Journal of Experimental Medicine, 1991